Results from a new study in treatment-naïve HIV patients have shown that Merck Sharp & Dohme’s (MSD) Isentress is effective as first-line medication for reducing viral load and increasing CD4 cell counts.

Isentress (raltegravir), a first-in-class integrase inhibitor, was found to be as effective as efavirenz, a standard first-line medication, at suppressing viral load to undetectable levels when used in combination therapy.

At week 48, patients taking raltegravir had significantly fewer side effects compared to the efavirenz group and there were greater increases in mean CD4 cell count recorded for the raltegravir group, although this was not statistically significant.

Raltegravir and efavirenz were administered in combination with two other anti-HIV medicines, tenofovir and emtricitabine.

London Chelsea and Westminster Hospital consultant in HIV medicine Mark Nelson said that these findings show that a raltegravir-based regimen was as effective as an efavirenz-based regimen.

“This study suggests that raltegravir in combination therapy with other antiretroviral treatments may become an important new treatment option for a broader spectrum of patients, including those who have not been previously treated with HIV therapy,” Nelson said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Raltegravir is approved in more than 80 countries across six continents for the treatment of HIV-1 infection in treatment-experienced adult patients in combination with other ARV agents.

MSD recently received a positive opinion from the European Union’s Committee for Medicinal Products for Human Use recommending expanded marketing authorisation for raltegravir for the treatment of HIV-1 infection in all adult patients, including treatment-naïve and treatment-experienced patients.